N/A
Manufactured by Acertis Pharmaceuticals, LLC
196 FDA adverse event reports analyzed
Last updated: 2026-04-15
PHENDIMETRAZINE TARTRATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Acertis Pharmaceuticals, LLC. The most commonly reported adverse reactions for PHENDIMETRAZINE TARTRATE include DRUG INEFFECTIVE, PAIN, HEADACHE, WEIGHT INCREASED, BACK PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PHENDIMETRAZINE TARTRATE.
Out of 57 classified reports for PHENDIMETRAZINE TARTRATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 196 FDA FAERS reports that mention PHENDIMETRAZINE TARTRATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, PAIN, HEADACHE, WEIGHT INCREASED, BACK PAIN, WRONG TECHNIQUE IN PRODUCT USAGE PROCESS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Acertis Pharmaceuticals, LLC in connection with PHENDIMETRAZINE TARTRATE. Always verify the specific product and NDC with your pharmacist.